Siemens Healthineers AG

TickerSHL.XETRA
Current Price –
Siemens Healthineers AG – stock chart

5-year stock timeline

2026 — Q3 FY2026 results; updated FY2026 outlook

Siemens Healthineers reported Q3 FY2026 results (April 1–June 30, 2026) with strong equipment order momentum (book-to-bill 1.27) offset by Diagnostics weakness, particularly in China. Tariff refunds in the U.S. raised EPS guidance while revenue-growth guidance was lowered. Management reduced the FY2026 comparable revenue-growth range to 3.5%–4.0% due to persistent Diagnostics headwinds, and raised adjusted basic EPS guidance to €2.35–€2.45 (from €2.20–€2.30) on the back of tariff refunds.

The market read mixed signals in the results. Very healthy order intake and margin support from one-off tariff refunds improved near-term earnings credibility, yet persistent Diagnostics headwinds and a lower revenue guide kept concerns about organic growth and China exposure alive. The stock narrative shifted to "resilient operational momentum with structural diagnostic headwinds," with emphasis on Precision Therapy and Varian as the growth offset.

Q3 FY2026 revenue reached €5,764m with adjusted EBIT margin around 19.1%. Adjusted basic EPS for the quarter was €0.70. Equipment book-to-bill stood at 1.27 [3][1].

2025 (fiscal year) — Post-Varian integration and midterm targets reaffirmed

After Varian acquisition integration continued through FY2025, Siemens Healthineers emphasized synergies and the strategic role of Varian and Precision Therapy in driving medium-term growth and margins. Management reiterated midterm ambitions including double-digit EPS progression.

Market perception transitioned from acquisition risk to a growth and upgrade story as Varian contributed recurring revenue and expanded the company's oncology footprint. Investors began valuing the company more on combined Imaging and Precision Therapy dynamics rather than Diagnostics alone.

Management had targeted at least €300m per annum in EBIT synergies from Varian by fiscal 2025 and reported improving contribution from Precision Therapy businesses in FY2025 commentary [14][13].

2024 — Ongoing Varian integration and segment reporting changes

Siemens Healthineers continued integrating Varian into its group structure as a distinct business within the Precision Therapy and oncology area. The company executed product launches and commercial rollouts for Varian platforms and emphasized cross-selling with Imaging and Diagnostics.

Investors increasingly treated Healthineers as a combined diagnostic-to-therapy platform with stronger long-term growth optionality. Near-term integration costs and execution risk were monitored, yet the strategic rationale of end-to-end cancer care supported a re-rating narrative for many shareholders.

Company statements described Varian as a new business segment following the 2021 closing and reported contribution to group adjusted EPS within the first 12 months after closing. Investor materials documented revenue and margin contributions by segment, with Precision Therapy growth outpacing Diagnostics in several quarters [14][8].

2022–2023 — Diagnostics weakness (China) and COVID-era demand normalization

Siemens Healthineers' Diagnostics segment experienced demand weakness and structural market changes in China and other regions during this period. Post-pandemic normalization in lab-testing volumes and competitive pressures affected Diagnostics revenue growth. Management adjusted segment commentary and guided for recovery over time while focusing investment in higher-margin Imaging and Precision Therapy.

Investor perception bifurcated: Diagnostics was viewed as a near-term headwind and potential value-trap area, while Imaging and the recently acquired Varian (Precision Therapy) were framed as the recovery and growth engines. The stock narrative emphasized portfolio rebalancing toward higher-growth, higher-margin businesses.

Company disclosures across FY2022–FY2023 quarterly and annual reports noted comparable revenue declines in Diagnostics in certain quarters and referenced Chinese market headwinds. Investors tracked segment comparable growth rates in quarterly reporting, with Diagnostics showing negative comparables versus Imaging and Precision Therapy growth [3][8].

2021 — Completion of Varian acquisition (transformative M&A)

Siemens Healthineers completed the acquisition of Varian Medical Systems on April 15, 2021 (announced August 2020). Varian became a new business segment, intended to create an end-to-end oncology franchise spanning imaging, diagnostics, and therapy, with an ambition to deliver at least €300m per annum in EBIT synergies by fiscal 2025. Management presented the deal as a centerpiece of Strategy 2025 ("Upgrading").

The market treated the deal as transformative, shifting Siemens Healthineers' identity from a diagnostics and imaging vendor toward an integrated cancer-care platform. Early investor debate centered on integration risk, purchase-price allocation, and near-term dilution versus the long-term strategic upside and cross-selling potential. Over time the narrative moved toward valuation on combined earnings power if synergies and cross-sell materialized.

The stated ambition was that Varian would positively contribute to adjusted basic EPS within the first 12 months and deliver at least €300m per annum in EBIT synergies by FY2025 [14].

Key risks and downside factors

Siemens Healthineers competes in a global medical technology and in vitro diagnostics market populated by large diversified players like GE HealthCare, Philips, Roche, Abbott, and Danaher, alongside specialist firms focused on imaging, diagnostics, and devices—Canon, Fujifilm, Thermo Fisher, Medtronic, Elekta among them. The competitive surface shifts constantly. Regulatory and reimbursement frameworks in Europe, the US, and China remain unpredictable. AI and software-first entrants are reshaping what diagnostics and imaging can do, often faster than incumbents expect. Lower-cost competitors and Chinese manufacturers press on pricing and margins. Beyond competition itself, the company faces operational vulnerabilities: supply-chain disruptions, geopolitical friction, and cybersecurity exposure all carry real weight [1].

  • Regulatory and reimbursement shifts—whether through changes to the EU's MDR/IVDR framework, FDA policy adjustments, NMPA requirements, or payer coverage decisions—can materially delay product approvals or compress pricing power [1].
  • Technology and competition risk: rapid advances in AI, software-first entrants, and lower-cost Chinese manufacturers could erode both market share and margins.
  • Operational and supply-chain risk emerges from component shortages, manufacturing disruptions, or geopolitical restrictions such as export controls and tariffs, all of which can delay deliveries and raise costs.
  • Cybersecurity and data privacy represent material risks. Breaches or inadequate security of clinical data and connected devices could trigger service disruptions, regulatory penalties, and reputational harm.

Competitive landscape

Siemens Healthineers competes across medical imaging, diagnostics, laboratory automation, image-guided therapy and related services within a landscape shaped by a handful of large diversified med-tech and diagnostics players, regional vendors offering lower-cost alternatives, and increasingly nimble software and AI companies. The business faces material headwinds from technological disruption driven by software and platform entrants, sustained pressure on pricing and reimbursement margins, the regulatory and compliance burden of operating across multiple jurisdictions, and competition from lower-cost manufacturers and vertically integrated rivals, particularly those based in China.

Private competitors

  • HeartFlow

    US-based clinical AI software company offering FFR-CT and advanced coronary analysis capabilities. Competes directly with Siemens' cardiac imaging and software platforms.

  • United Imaging Healthcare (partly private/state-affiliated)

    A Chinese manufacturer of advanced imaging and radiotherapy equipment is expanding internationally, competing primarily on price and hardware capabilities in emerging markets while also gaining traction in select developed markets.

  • Aidoc

    Israeli medical-imaging AI vendor offering radiology decision-support tools that compete with Siemens' AI and software offerings for image analysis and workflow optimization.

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Performance Figures of Siemens Healthineers AG

in EUR

1M High / Low
45.20 / 40.88
52W High / Low
47.26 / 32.81
5Y High / Low
67.66 / 32.81
1M
+5.79%
3M
+9.05%
6M
+27.07%
1Y
+8.52%
3Y
-6.97%
5Y
-27.50%

Relative Performance vs Benchmarks

PeriodSiemens Healthineers AG vs DAX vs S&P 500 (SPY)
1M +5.79% +4.08% +10.84%
3M +9.05% +10.58% +13.45%
6M +27.07% +23.66% +28.64%
1Y +8.52% -2.59% -2.87%
3Y -6.97% -68.82% -73.65%
5Y -27.50% -86.76% -94.01%

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

PeriodP/E RatioP/S RatioP/B RatioP/CF Ratio
Current22.02.12.517.0
1Y ago21.72.02.615.1
3Y ago37.12.63.130.9
5Y ago42.74.14.526.5

Frequently Asked Questions

Where is the Siemens Healthineers AG stock traded?

The Siemens Healthineers AG stock trades under the ticker SHL.XETRA on the XETRA exchange. ISIN: DE000SHL1006.

What does Siemens Healthineers AG do?

Siemens Healthineers AG is a company characterized by the following investment thesis:

What are the key metrics for SHL.XETRA?

Key metrics for SHL.XETRA include valuation (P/E 22, P/S 2.1, P/B 2.5), profitability (profit margin 9.37%, ROE 11.69%), and growth (revenue –, earnings –). Market capitalization is 48.46B EUR. These metrics give an overview of the company's financial performance and valuation.

How has Siemens Healthineers AG's stock price performed?

Siemens Healthineers AG's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

How is SHL.XETRA valued?

SHL.XETRA has the following valuation metrics: P/E Ratio: 22, P/S Ratio: 2.1, P/B Ratio: 2.5. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Does SHL.XETRA pay dividends?

Yes, SHL.XETRA pays dividends with a dividend yield of 2.3%. Dividends can be an important component of the total return on an investment.

What are the key risks when investing in SHL.XETRA?

Key risks for SHL.XETRA include: Siemens Healthineers competes in a global medical technology and in vitro diagnostics market populated by large diversified players like GE HealthCare, Philips, Roche, Abbott, and Danaher, alongside specialist firms focused on imaging, diagnostics, and devices—Canon, Fujifilm, Thermo Fisher, Medtronic, Elekta among them. The competitive surface shifts constantly. Regulatory and reimbursement frameworks in Europe, the US, and China remain unpredictable. AI and software-first entrants are reshaping what diagnostics and imaging can do, often faster than incumbents expect. Lower-cost competitors and Chinese manufacturers press on pricing and margins. Beyond competition itself, the company faces operational vulnerabilities: supply-chain disruptions, geopolitical friction, and cybersecurity exposure all carry real weight [1].
  • Regulatory and reimbursement shifts—whether through changes to the EU's MDR/IVDR framework, FDA policy adjustments, NMPA requirements, or payer coverage decisions—can materially delay product approvals or compress pricing power [1].
  • Technology and competition risk: rapid advances in AI, software-first entrants, and lower-cost Chinese manufacturers could erode both market share and margins.
  • Operational and supply-chain risk emerges from component shortages, manufacturing disruptions, or geopolitical restrictions such as export controls and tariffs, all of which can delay deliveries and raise costs.
  • Cybersecurity and data privacy represent material risks. Breaches or inadequate security of clinical data and connected devices could trigger service disruptions, regulatory penalties, and reputational harm.
Investors should consider these risk factors carefully before making an investment decision.

Who are the main competitors of Siemens Healthineers AG?

Siemens Healthineers AG competes with several listed peers in its sector. Siemens Healthineers competes across medical imaging, diagnostics, laboratory automation, image-guided therapy and related services within a landscape shaped by a handful of large diversified med-tech and diagnostics players, regional vendors offering lower-cost alternatives, and increasingly nimble software and AI companies. The business faces material headwinds from technological disruption driven by software and platform entrants, sustained pressure on pricing and reimbursement margins, the regulatory and compliance burden of operating across multiple jurisdictions, and competition from lower-cost manufacturers and vertically integrated rivals, particularly those based in China.
  • GE HealthCare Technologies Inc. (GEHC.NYSE)
  • Roche Holding AG (ROG.SIX)
  • Abbott Laboratories (ABT.NYSE)
  • Thermo Fisher Scientific Inc. (TMO.NYSE)
  • Danaher Corporation (DHR.NYSE)
  • Medtronic plc (MDT.NYSE)
  • Stryker Corporation (SYK.NYSE)
  • Mindray Medical International Limited (300760.SZ)
These competitors influence pricing power, growth opportunities and relative valuation.

When does Siemens Healthineers AG report earnings?

Siemens Healthineers AG's next earnings report date is February 4, 2027.

Key Metrics

Market Capitalization
48.46B EUR
P/E Ratio
21.98
Analyst Target Price
–

Valuation Metrics

P/S Ratio
2.05
P/B Ratio
2.48

Profitability Metrics

Profit Margin
9.37%
Operating Margin
14.13%
Return on Equity
11.69%
Return on Assets
4.86%

Growth Metrics

Revenue Growth
–
Earnings Growth
–

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

YearDividendYield at paymentAvg. yield
20261.00 EUR2.35%1.85%
20250.95 EUR1.66%
20240.95 EUR1.86%
20230.95 EUR1.85%
20220.85 EUR1.52%
20210.80 EUR1.64%
20200.80 EUR1.94%
20190.70 EUR1.98%

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Historical earnings performance

62.9%
Beat estimate
34.3%
Miss estimate
+11.39%
Avg surprise when beat
-8.11%
Avg surprise when miss

Reports analyzed: 35

Upcoming earnings report

February 4, 2027
Next earnings date

Analyst estimates for upcoming periods

Next year
September 30, 2028
Consensus2.63
Range2.37 – 2.81
19 analysts
Est. growth vs prior: 13.92%
Revisions: 7d ↑0 ↓0 · 30d ↑5 ↓5
Next quarter
March 31, 2027
Consensus0.57
Range0.54 – 0.61
3 analysts
Est. growth vs prior: 7.53%
Revisions: 7d ↑1 ↓0 · 30d ↑1 ↓0

Key financial figures

All figures in EUR

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.

20262025202420232022
Revenue23.63B23.38B22.36B21.68B21.71B
Operating income (EBIT)3.19B3.44B3.30B2.44B3.06B
Net income2.21B2.14B1.94B1.51B2.04B
Free cash flow2.44B2.27B1.77B1.28B1.65B
Total assets46.71B44.37B46.05B46.68B49.06B
Equity19.85B18.04B18.20B18.08B19.84B
Net debt12.20B12.89B13.53B-1.01B-704.00M
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon